Gordon SM, et al. - Using the entire military electronic medical record between 2005 and 2016, researchers assessed the risk of Scleroderma Renal Crisis (SRC) in relation to the use of systemic sclerosis (SSc) medications. They compared 31 cases who subsequently developed SRC to 322 SSc without SRC disease controls regarding the use of ace inhibitor (ACEi), angiotensin receptor blocker, calcium channel blocker, non-steroidal anti-inflammatory drug, endothelin receptor blocker, fluticasone, and mycophenolate mofetil following SSc diagnosis. An increased risk for SRC was reported in relation to ACEi use at SSC diagnosis. It was suggested to be a possible passive marker of established SRC risk factors, such as proteinuria, or evolving disease. More close surveillance for SRC was recommended in SSC patients that need ACEi.